SPECIFIC AIMS Kidney transplantation (KT) is the optimal treatment for end-stage kidney disease (ESKD). It reduces mortality, improves quality of life, and is less costly than dialysis. Further, living donor KT (LDKT) is better than deceased donor KT (DDKT) because: (a) patients who can identify a living donor will get a KT much more quickly than ones awaiting DDKT and, (b) LDKT yields better outcomes than DDKT by improving cost effectiveness, reducing morbidity, and increasing long-term survival. The KT evaluation process, which occurs after patients have been referred for KT, is lengthy, time consuming, and burdensome to the patient. It requires patients to complete numerous tests (e.g., blood work, cardiac checks, pap smear, etc.) in order to be presented to the transplant team and accepted for KT. Although some variation between centers exists, typically patients must complete testing on their own, and ensure that their clinical providers forward results to the transplant team. This requires significant oversight and follow-up by the patient with each clinical provider.